AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06454669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
Trial: NCT06763172
Drug: Caffeine (200 mg)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Trial: NCT06763172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Trial: NCT06585787
Drug: KarXT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06585787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04566887
Drug: R-CHOP chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP chemotherapy
Trial: NCT06753786
Drug: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
Trial: NCT06753786
Drug: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
Trial: NCT06753526
Drug: L-Arginine, 500 Mg Oral Capsule
RxNorm normalized name: L-Arginine, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group 2by twice dose
Trial: NCT06777316
Drug: CGT4859
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGT4859 is a selective FGFR2/3 inhibitor
Trial: NCT06532396
Drug: QRL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Trial: NCT06532396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
Trial: NCT05605496
Drug: anti-PD-1/PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
Trial: NCT05732831
Drug: TNG462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally
Trial: NCT06747585
Drug: ALE.P02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALE.P02, will be administered by IV infusion according to the assigned arms.
Trial: NCT06746064
Drug: Placebo (Part 1 - SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo matching CHF10073 for each cohort
Trial: NCT06771544
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06775483
Drug: JSKN016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously according to protocol.
Trial: NCT06750783
Drug: Xuezhikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;
Trial: NCT06775405
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Trial: NCT06775405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Trial: NCT06776445
Drug: minocycline combined with hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
Trial: NCT06776198
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
Trial: NCT06549595
Drug: AZD0486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a fully human bispecific monoclonal IgG4 antibody
Trial: NCT06549595
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Trial: NCT06549595
Drug: R-CVP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, Cyclophosphamide, Vincristine and Prednisone
Trial: NCT04886258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06756334
Drug: [18F]AlF-PSMA-N5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Trial: NCT06757738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, dosage form - capsules, dosing regimen - QD
Trial: NCT06638307
Drug: MEN2312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN2312 administered as oral tablets.
Trial: NCT06776952
Drug: XNW5004 ; Chidamide placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNW5004 + Chidamide placebo
Trial: NCT06776952
Drug: XNW5004 placebo; Chidamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNW5004 placebo + Chidamide
Trial: NCT06614192
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06755944
Drug: XY03-EA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days.
Trial: NCT06769048
Drug: Placebo-matching BI 1584862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching BI 1584862
Trial: NCT06427798
Drug: [203Pb]VMT-alpha-NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.
Trial: NCT04550377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active medication
Trial: NCT06772168
Drug: CMG190303(Dapagliflozin/Rosuvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
Trial: NCT06772168
Drug: Comparator 1: Dapagliflozin/Rosuvastatin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
Trial: NCT06772168
Drug: Rosuvastatin/Dapagliflozin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
Trial: NCT06744569
Drug: CU-10101
RxNorm normalized name: Cu 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
Trial: NCT05470114
Drug: LEO 138559
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 138559 is an antibody given by subcutaneous injection.
Trial: NCT05470114
Drug: Dupixent®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupixent® is an antibody given by subcutaneous injection.
Trial: NCT06766578
Drug: Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.
Trial: NCT06766578
Drug: Adjuvant therapy(SOX chemotherapy)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
Trial: NCT06755541
Drug: Fenofibrate in Combination With Ursodeoxycholic Acid
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Fenofibrate 200 mg Capsules
Trial: NCT06764017
Drug: CHiR-DEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.
Trial: NCT06780345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.
Trial: NCT06773091
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.
Trial: NCT05720065
Drug: Isotonic saline 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized double-blind administration
Trial: NCT05486182
Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of one dose of 18F FES for PET/CT imaging
Trial: NCT05170399
Drug: AREXVY, ABRYSVO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory Syncytial Virus Vaccine
Trial: NCT05540574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo given orally
Trial: NCT06294990
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two years treatment with testosterone
Trial: NCT06083207
Drug: IBI3003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Trial: NCT06466798
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
Trial: NCT06088004
Drug: ABO2011 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
Trial: NCT05868369
Drug: Standard pain management regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
Trial: NCT06619600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo qd
Trial: NCT04040452
Drug: Continuous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
Trial: NCT05326035
Drug: WJ05129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
Trial: NCT05964140
Drug: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Trial: NCT04594642
Drug: AZD0486 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
Trial: NCT05357989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC (vegetarian source) capsule shells
Trial: NCT03984565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
Trial: NCT06667869
Drug: Sedative
RxNorm normalized name: Sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
Trial: NCT06073132
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Trial: NCT05940493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06489431
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglycoside antibiotic irrigation
Trial: NCT06013956
Drug: Carbidopa 25/Levodopa 100Mg Tab
RxNorm normalized name: CARBIDOPA 25/LEVODOPA 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-parkinsonian medication.
Trial: NCT04994509
Drug: Placebo SC LEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via SC injections
Trial: NCT04994509
Drug: PTM F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT04994509
Drug: PTM F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT06315881
Drug: Cigarette
RxNorm normalized name: CIGARETTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoke usual brand cigarette
Trial: NCT06498713
Drug: Acetaminophen 650 mg Oral Tablet
RxNorm normalized name: acetaminophen 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg pills
Trial: NCT06498713
Drug: Acetaminophen 650mg Liquid
RxNorm normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg liquid
Trial: NCT05667805
Drug: Platelet Concentrate
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal use (standard treatment)
Trial: NCT06546670
Drug: ITU512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.
Trial: NCT06546670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
Trial: NCT04517435
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
Trial: NCT04517435
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
Trial: NCT06774313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT06774313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC Injection
Trial: NCT06774885
Drug: Folic Acid 1 Mg Oral Tablet
RxNorm normalized name: FOLIC ACID 1 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral folic acid tablet
Trial: NCT06774885
Drug: Folic Acid 5 Mg Oral Tablet
RxNorm normalized name: folic acid 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral folic acid tablet
Trial: NCT06349473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as single SC injection.
Trial: NCT05661682
Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralement without Manganese Sulfate
Trial: NCT05071352
Drug: Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
Trial: NCT05340582
Drug: Acetaminophen Injection
RxNorm normalized name: acetaminophen Injection
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
Trial: NCT05340582
Drug: Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
Trial: NCT05003063
Drug: Donepzil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test
Trial: NCT05003063
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test
Trial: NCT05849298
Drug: AAA617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
Trial: NCT05849298
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed by the local investigator
Trial: NCT05019027
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and until subsequently discontinued (or the lowest dose the subject can safely tolerate).~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol
Trial: NCT05629689
Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Trial: NCT05629689
Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Trial: NCT05062980
Drug: Investigator's Treatment of Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
Trial: NCT06430580
Drug: Hydrocortisone Oral
RxNorm normalized name: hydrocortisone Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg hydrocortisone, single oral dose
Trial: NCT06128980
Drug: GDMT
RxNorm normalized name: Guideline-Directed Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi